Age group: 6 to 17 years old
Gender: Male or Female
Duration: Up to 52 weeks approximately
Compensation: Up to: $4.050
About this study:
This 48-week, Phase 3, OL-LTE study is being conducted as part of a clinical development program to evaluate the long-term safety and continued efficacy of tapinarof cream, 1% for the treatment of Atopic Dermatitis in children and adults.
Who can participate?
Participants must be Male and female ages 2 years to < 18 years at the time of consent with clinical diagnosis of Atopic Dermatitis.Atopic Dermatitis present for at least 6 months for ages 6 years old and above or 3 months for ages 2 to 5 years old, confirmed by prior medical documentation and/or according to the subject/caregiver report.
Where is the study taking place?
The study is being conducted at our facility in Palmetto Medical Plaza.
NCT05142774
